GPC2 Is a Potential Diagnostic, Immunological, and Prognostic Biomarker in Pan-Cancer. 2022

Guoming Chen, and Dongqiang Luo, and Nan Zhong, and Danyun Li, and Jiyuan Zheng, and Hui Liao, and Zhuoyao Li, and Xiaoxiao Lin, and Qiqi Chen, and Cheng Zhang, and Yuanjun Lu, and Yau-Tuen Chan, and Qing Ren, and Ning Wang, and Yibin Feng
School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.

Glypican 2 (GPC2), a member of glypican (GPC) family genes, produces proteoglycan with a glycosylphosphatidylinositol anchor. It has shown its ascending significance in multiple cancers such as neuroblastoma, malignant brain tumor, and small-cell lung cancer. However, no systematic pan-cancer analysis has been conducted to explore its function in diagnosis, prognosis, and immunological prediction. By comprehensive use of datasets from The Cancer Genome Atlas (TCGA), Cancer Cell Line Encyclopedia (CCLE), Genotype-Tissue Expression Project (GTEx), cBioPortal, Human Protein Atlas (HPA), UALCAN, StarBase, and Comparative Toxicogenomics Database (CTD), we adopted bioinformatics methods to excavate the potential carcinogenesis of GPC2, including dissecting the correlation between GPC2 and prognosis, gene mutation, immune cell infiltration, and DNA methylation of different tumors, and constructed the competing endogenous RNA (ceRNA) networks of GPC2 as well as explored the interaction of GPC2 with chemicals and genes. The results indicated that GPC2 was highly expressed in most cancers, except in pancreatic adenocarcinoma, which presented at a quite low level. Furthermore, GPC2 showed the early diagnostic value in 16 kinds of tumors and was positively or negatively associated with the prognosis of different tumors. It also verified that GPC2 was a gene associated with most immune-infiltrating cells in pan-cancer, especially in thymoma. Moreover, the correlation with GPC2 expression varied depending on the type of immune-related genes. Additionally, GPC2 gene expression has a correlation with DNA methylation in 20 types of cancers. Through pan-cancer analysis, we discovered and verified that GPC2 might be useful in cancer detection for the first time. The expression level of GPC2 in a variety of tumors is significantly different from that of normal tissues. In addition, the performance of GPC2 in tumorigenesis and tumor immunity also confirms our conjecture. At the same time, it has high specificity and sensitivity in the detection of cancers. Therefore, GPC2 can be used as an auxiliary indicator for early tumor diagnosis and a prognostic marker for many types of tumors.

UI MeSH Term Description Entries
D010190 Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA). Cancer of Pancreas,Pancreatic Cancer,Cancer of the Pancreas,Neoplasms, Pancreatic,Pancreas Cancer,Pancreas Neoplasms,Pancreatic Acinar Carcinoma,Pancreatic Carcinoma,Acinar Carcinoma, Pancreatic,Acinar Carcinomas, Pancreatic,Cancer, Pancreas,Cancer, Pancreatic,Cancers, Pancreas,Cancers, Pancreatic,Carcinoma, Pancreatic,Carcinoma, Pancreatic Acinar,Carcinomas, Pancreatic,Carcinomas, Pancreatic Acinar,Neoplasm, Pancreas,Neoplasm, Pancreatic,Neoplasms, Pancreas,Pancreas Cancers,Pancreas Neoplasm,Pancreatic Acinar Carcinomas,Pancreatic Cancers,Pancreatic Carcinomas,Pancreatic Neoplasm
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D053673 Glypicans A family of GLYCOSYLPHOSPHATIDYLINOSITOL-anchored, cell-surface heparan sulfate proteoglycans that may play a role in CELL GROWTH PROCESSES and CELL DIFFERENTIATION by modulating ligand-receptor interactions. Glypican,Glypican 3,Glypican-1,Glypican-2,Glypican-3,Glypican-4,Glypican-5,Glypican 1,Glypican 2,Glypican 4,Glypican 5

Related Publications

Guoming Chen, and Dongqiang Luo, and Nan Zhong, and Danyun Li, and Jiyuan Zheng, and Hui Liao, and Zhuoyao Li, and Xiaoxiao Lin, and Qiqi Chen, and Cheng Zhang, and Yuanjun Lu, and Yau-Tuen Chan, and Qing Ren, and Ning Wang, and Yibin Feng
October 2023, Scientific reports,
Guoming Chen, and Dongqiang Luo, and Nan Zhong, and Danyun Li, and Jiyuan Zheng, and Hui Liao, and Zhuoyao Li, and Xiaoxiao Lin, and Qiqi Chen, and Cheng Zhang, and Yuanjun Lu, and Yau-Tuen Chan, and Qing Ren, and Ning Wang, and Yibin Feng
May 2024, Asian journal of surgery,
Guoming Chen, and Dongqiang Luo, and Nan Zhong, and Danyun Li, and Jiyuan Zheng, and Hui Liao, and Zhuoyao Li, and Xiaoxiao Lin, and Qiqi Chen, and Cheng Zhang, and Yuanjun Lu, and Yau-Tuen Chan, and Qing Ren, and Ning Wang, and Yibin Feng
October 2023, Scientific reports,
Guoming Chen, and Dongqiang Luo, and Nan Zhong, and Danyun Li, and Jiyuan Zheng, and Hui Liao, and Zhuoyao Li, and Xiaoxiao Lin, and Qiqi Chen, and Cheng Zhang, and Yuanjun Lu, and Yau-Tuen Chan, and Qing Ren, and Ning Wang, and Yibin Feng
March 2024, Translational cancer research,
Guoming Chen, and Dongqiang Luo, and Nan Zhong, and Danyun Li, and Jiyuan Zheng, and Hui Liao, and Zhuoyao Li, and Xiaoxiao Lin, and Qiqi Chen, and Cheng Zhang, and Yuanjun Lu, and Yau-Tuen Chan, and Qing Ren, and Ning Wang, and Yibin Feng
April 2023, Aging,
Guoming Chen, and Dongqiang Luo, and Nan Zhong, and Danyun Li, and Jiyuan Zheng, and Hui Liao, and Zhuoyao Li, and Xiaoxiao Lin, and Qiqi Chen, and Cheng Zhang, and Yuanjun Lu, and Yau-Tuen Chan, and Qing Ren, and Ning Wang, and Yibin Feng
August 2025, Discover oncology,
Guoming Chen, and Dongqiang Luo, and Nan Zhong, and Danyun Li, and Jiyuan Zheng, and Hui Liao, and Zhuoyao Li, and Xiaoxiao Lin, and Qiqi Chen, and Cheng Zhang, and Yuanjun Lu, and Yau-Tuen Chan, and Qing Ren, and Ning Wang, and Yibin Feng
January 2024, Scientific reports,
Guoming Chen, and Dongqiang Luo, and Nan Zhong, and Danyun Li, and Jiyuan Zheng, and Hui Liao, and Zhuoyao Li, and Xiaoxiao Lin, and Qiqi Chen, and Cheng Zhang, and Yuanjun Lu, and Yau-Tuen Chan, and Qing Ren, and Ning Wang, and Yibin Feng
January 2021, Frontiers in genetics,
Guoming Chen, and Dongqiang Luo, and Nan Zhong, and Danyun Li, and Jiyuan Zheng, and Hui Liao, and Zhuoyao Li, and Xiaoxiao Lin, and Qiqi Chen, and Cheng Zhang, and Yuanjun Lu, and Yau-Tuen Chan, and Qing Ren, and Ning Wang, and Yibin Feng
April 2024, Biomolecules & biomedicine,
Guoming Chen, and Dongqiang Luo, and Nan Zhong, and Danyun Li, and Jiyuan Zheng, and Hui Liao, and Zhuoyao Li, and Xiaoxiao Lin, and Qiqi Chen, and Cheng Zhang, and Yuanjun Lu, and Yau-Tuen Chan, and Qing Ren, and Ning Wang, and Yibin Feng
March 2024, Scientific reports,
Copied contents to your clipboard!